For many years, the only approved first- and second-line treatment options for CRC were surgical interventions followed by chemotherapy regimens and combinations with antibodies against epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) if indicated [4]. This evidence concerns the gene EGFR and colorectal carcinoma.